Anchor Side Chains of Short Peptide Fragments Trigger Ligand-Exchange of Class II MHC Molecules

Class II MHC molecules display peptides on the cell surface for the surveillance by CD4+ T cells. To ensure that these ligands accurately reflect the content of the intracellular MHC loading compartment, a complex processing pathway has evolved that delivers only stable peptide/MHC complexes to the surface. As additional safeguard, MHC molecules quickly acquire a ‘non-receptive’ state once they have lost their ligand. Here we show now that amino acid side chains of short peptides can bypass these safety mechanisms by triggering the reversible ligand-exchange. The catalytic activity of dipeptides such as Tyr-Arg was stereo-specific and could be enhanced by modifications addressing the conserved H-bond network near the P1 pocket of the MHC molecule. It affected both antigen-loading and ligand-release and strictly correlated with reported anchor preferences of P1, the specific target site for the catalytic side chain of the dipeptide. The effect was evident also in CD4+ T cell assays, where the allele-selective influence of the dipeptides translated into increased sensitivities of the antigen-specific immune response. Molecular dynamic calculations support the hypothesis that occupation of P1 prevents the ‘closure’ of the empty peptide binding site into the non-receptive state. During antigen-processing and -presentation P1 may therefore function as important “sensor” for peptide-load. While it regulates maturation and trafficking of the complex, on the cell surface, short protein fragments present in blood or lymph could utilize this mechanism to alter the ligand composition on antigen presenting cells in a catalytic way.

[1]  O. Rötzschke,et al.  “Chemical Analogues” of HLA-DM Can Induce a Peptide-receptive State in HLA-DR Molecules* , 2004, Journal of Biological Chemistry.

[2]  L. Santambrogio,et al.  Abundant empty class II MHC molecules on the surface of immature dendritic cells. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[3]  C. Watts,et al.  Antigen processing in the endocytic compartment. , 2001, Current opinion in immunology.

[4]  S. Sadegh-Nasseri,et al.  Stable peptide binding to MHC class II molecule is rapid and is determined by a receptive conformation shaped by prior association with low affinity peptides. , 1999, Journal of immunology.

[5]  P. Cresswell,et al.  HLA-DR molecules from an antigen-processing mutant cell line are associated with invariant chain peptides , 1992, Nature.

[6]  Guttorm Haraldsen,et al.  Primary antitumor immune response mediated by CD4+ T cells. , 2005, Immunity.

[7]  Eric O Long,et al.  HLA‐DR‐restricted presentation of purified myelin basic protein is independent of intracellular processing , 1997, European journal of immunology.

[8]  Don C. Wiley,et al.  Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide , 1994, Nature.

[9]  L. Santambrogio,et al.  MHC class II compartment subtypes: structure and function. , 2006, Current opinion in immunology.

[10]  J. Strominger,et al.  Extracellular antigen processing and presentation by immature dendritic cells. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[11]  G. Hämmerling,et al.  Self-Release of CLIP in Peptide Loading of HLA-DR Molecules , 1995, Science.

[12]  O. Rötzschke,et al.  Small-molecular compounds enhance the loading of APC with encephalitogenic MBP protein. , 2003, Journal of autoimmunity.

[13]  D. Zaller,et al.  Mediation by HLA-DM of dissociation of peptides from HLA-DR , 1995, Nature.

[14]  Scheherazade Sadegh-Nasseri,et al.  Hla-Dm Recognizes the Flexible Conformation of Major Histocompatibility Complex Class II , 2000, The Journal of experimental medicine.

[15]  L. Stern,et al.  Sodium dodecyl sulfate stability of HLA-DR1 complexes correlates with burial of hydrophobic residues in pocket 1. , 1999, Journal of immunology.

[16]  H. Kalbacher,et al.  New ligands binding to the human leukocyte antigen class II molecule DRB1*0101 based on the activity pattern of an undecapeptide library. , 1996, European journal of biochemistry.

[17]  Gerrit Groenhof,et al.  GROMACS: Fast, flexible, and free , 2005, J. Comput. Chem..

[18]  P Wordsworth,et al.  Critical role for the Val/Gly86 HLA-DR beta dimorphism in autoantigen presentation to human T cells. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[19]  P. van Endert,et al.  A chaperone-assisted high yield system for the production of HLA-DR4 tetramers in insect cells. , 2004, Journal of immunological methods.

[20]  Kedar Narayan,et al.  HLA-DM targets the hydrogen bond between the histidine at position β81 and peptide to dissociate HLA-DR–peptide complexes , 2007, Nature Immunology.

[21]  R. Doebele,et al.  Determination of the HLA-DM interaction site on HLA-DR molecules. , 2000, Immunity.

[22]  K Schulten,et al.  VMD: visual molecular dynamics. , 1996, Journal of molecular graphics.

[23]  P. Ricciardi-Castagnoli,et al.  Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria , 2001, Nature Immunology.

[24]  Lars Fugger,et al.  MHC class II proteins and disease: a structural perspective , 2006, Nature Reviews Immunology.

[25]  J. Strominger,et al.  Antigen‐specific elimination of T cells induced by oligomerized hemagglutinin (HA) 306–318 , 2000, European journal of immunology.

[26]  G. Hämmerling,et al.  HLA-DM acts as a molecular chaperone and rescues empty HLA-DR molecules at lysosomal pH. , 1997, Immunity.

[27]  Leah M. Octavio,et al.  Empty Class II Major Histocompatibility Complex Created by Peptide Photolysis Establishes the Role of DM in Peptide Association* , 2007, Journal of Biological Chemistry.

[28]  S. Anderton,et al.  Immunological tolerance using synthetic peptides--basic mechanisms and clinical application. , 2006, Current molecular medicine.

[29]  J. Woody,et al.  Human T-cell clones recognize chemically synthesized peptides of influenza haemagglutinin , 1982, Nature.

[30]  Hans-Georg Rammensee,et al.  MHC Ligands and Peptide Motifs , 1998, Molecular Biology Intelligence Unit.

[31]  J. McCluskey,et al.  Immunodominant CD4+ responses identified in a patient vaccinated with full-length NY-ESO-1 formulated with ISCOMATRIX adjuvant. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[32]  J. Strominger,et al.  Ligand Exchange of Major Histocompatibility Complex Class II Proteins Is Triggered by H-bond Donor Groups of Small Molecules* , 2002, The Journal of Biological Chemistry.

[33]  M. Vrljic,et al.  Formation of a highly peptide-receptive state of class II MHC. , 1998, Immunity.

[34]  E. von Hofe,et al.  MHC Class II Allosteric Site Drugs: New Immunotherapeutics for Malignant, Infectious and Autoimmune Diseases * , 2001, Scandinavian journal of immunology.

[35]  Christian Freund,et al.  Small Organic Compounds Enhance Antigen Loading of Class II Major Histocompatibility Complex Proteins by Targeting the Polymorphic P1 Pocket*♦ , 2006, Journal of Biological Chemistry.

[36]  Eric O Long,et al.  Antigen presentation mediated by recycling of surface HLA-DR molecules , 1995, Nature.

[37]  A. Woods,et al.  An HLA-DR1 Transgene Confers Susceptibility to Collagen-induced Arthritis Elicited with Human Type II Collagen , 1997, The Journal of experimental medicine.

[38]  P. Cresswell,et al.  HLA-DM Interactions with Intermediates in HLA-DR Maturation and a Role for HLA-DM in Stabilizing Empty HLA-DR Molecules , 1996, The Journal of experimental medicine.